Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch

Feb 04 2013

• By Emily Hayes

Related Content

Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking

Jan 07 2013

Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?

May 02 2011

Takeda Re-Files DPP-4 Inhibitor Alogliptin, Plays Up Combo With Actos

Aug 01 2011

Riding High, <em>Victoza</em> Hopes To Gain Ground Over Popular DPP-4s With Label Change

Apr 16 2012

Anatomy Of The <i>Avandia</i> Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views

Oct 04 2010

Related Companies

Takeda Pharmaceutical Co. Ltd.

H. Lundbeck A/S

Orexigen Therapeutics, Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

GSK plc

Additional Topics

Regulation Approvals BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window